Gambling therapy flunks Phase II trial

A Phase II/III trial of Somaxon Pharmaceuticals' nalmefene for the treatment of pathological gambling failed to demonstrate a statistically significant difference compared to placebo. The trial evaluated 20 mg and 40 mg of oral nalmefene hydrochloride. Both doses missed the secondary endpoints as well. Ken Cohen, Somaxon's President and CEO, noted, "The results of this clinical trial for nalmefene are disappointing. We will now perform a careful analysis of all of our nalmefene data and our assumptions underlying that program to determine what the next steps should be." Earlier this year Somaxon touted Phase II data for oral nalmefene hydrochloride for smoking cessation.

- check out this press release on the study results

Related Article:
BioTie drug helps blunt thrill of gambling. Report
Somaxon touts mid-stage data on smoking cessation. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.